本栏目为您提供冠心病、高血压 、血脂异常、心律失常、瓣膜性心脏病、心肌梗塞、先心病 、肺栓塞、心肌病、心力衰竭、肺动脉高压、外周心血管病、糖尿病、脑卒中、代谢综合征、急性冠脉综合征、心血管综合 相关幻灯课件,您可以免费下载使用
点击显示 收起
文件类型:PPT | 文件大小:35KB | 上传时间:06-01-03
摘要:CAST: Cardiac Arrhythmia Suppression Trial PurposeTo determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic ventricular arrhythmias after MI reduces ...
文件类型:PPT | 文件大小:51KB | 上传时间:06-01-03
摘要:CARE: Cholesterol and Recurrent Events TrialPurposeTo determine whether pravastatin reduces risk of coronary events in patients with average cholesterol and previous MIReferenceSacks FM, Pfeffer MA...
文件类型:PPT | 文件大小:38KB | 上传时间:06-01-03
摘要:BHAT: Beta-blocker Heart Attack Trial PurposeTo determine whether the β-blocker propranolol reduces all-cause mortality in patients with acute MIReferenceβ-Blocker Heart Attack Trial Research Gro...
文件类型:PPT | 文件大小:52KB | 上传时间:06-01-03
摘要:BEST: Beta-blocker Evaluation Survival TrialPurposeTo determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced heart failureReferenceThe BEST Investigat...
文件类型:PPT | 文件大小:50KB | 上传时间:06-01-03
摘要:AIRE: Acute Infarction Ramipril Efficacy study PurposeTo determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart failure after MIReferenceThe Acute Infarct...
文件类型:PPT | 文件大小:52KB | 上传时间:06-01-03
摘要:PROSPER: PROspective Study of Pravastatin in the Elderly at RiskPurposeTo determine whether pravastatin reduces morbidity and mortality in elderly men and women at risk of vascular diseaseReference...
文件类型:PPT | 文件大小:55KB | 上传时间:06-01-03
摘要:OPTIMAAL: Optimal Trial In Myocardial Infarction with the Angiotensin Antagonist LosartanPurposeTo determine whether the angiotensin II receptor blocker losartan is superior or inferior to the angi...
文件类型:PPT | 文件大小:52KB | 上传时间:06-01-03
摘要:HPS: Heart Protection StudyPurposeTo determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease, but all at high risk, and with a broad range ...
文件类型:PPT | 文件大小:51KB | 上传时间:06-01-03
摘要:HOPE: Heart Outcomes Prevention Evaluation study PurposeTo evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence of cardiovascular morbidity and mortality in...
文件类型:PPT | 文件大小:40KB | 上传时间:06-01-03
摘要:EUROPA: EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery diseasePurposeTo determine whether the ACE inhibitor perindopril reduces cardiovascular risk in pati...
文件类型:PPT | 文件大小:39KB | 上传时间:06-01-03
摘要:ESTEEM: Efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial infarction PurposeTo compare the efficacy and safety of four doses of oral ximelaga...
文件类型:PPT | 文件大小:52KB | 上传时间:06-01-03
摘要:COMET: Carvedilol Or Metoprolol European TrialPurposeTo compare the effects of carvedilol (a β1-, β2- and α1-receptor blocker) and short-acting metoprolol tartrate (a β1-receptor blocker) on cl...
文件类型:PPT | 文件大小:40KB | 上传时间:06-01-03
摘要:CHARM-Overall: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - OverallPurposeTo determine whether the angiotensin II receptor blocker candesartan reduces all-caus...
文件类型:PPT | 文件大小:40KB | 上传时间:06-01-03
摘要:CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved PurposeTo determine whether the angiotensin II receptor blocker candesartan is benefici...
文件类型:PPT | 文件大小:39KB | 上传时间:06-01-03
摘要:CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - AlternativePurposeTo determine whether the angiotensin II receptor blocker candesartan is benef...
文件类型:PPT | 文件大小:40KB | 上传时间:06-01-03
摘要:CHARM Added: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - AddedPurposeTo determine whether addition of the angiotensin II receptor blocker candesartan is benef...
文件类型:PPT | 文件大小:129KB | 上传时间:06-01-03
摘要:介绍了代谢紊乱和代谢综合征的行为干预方法:饮食控制、锻炼、控制体重。Lifestyle Interventions: Dietary Therapy, Physical Activity, Weight Control Neil J。2010NowPrimary Prevention: Status and Goals i...
文件类型:PPT | 文件大小:767KB | 上传时间:06-01-03
摘要:Fonarow, MD1970s1988Evolution of the NCEP Guidelines19932001ATP IATP IIATP IIIFraminghamMRFITLRC-CPPTCoronary Drug ProjectHelsinki Heart StudyCLAS (angio)Angiographic Trials(FATS, POSCH, SCOR, STAR...
文件类型:PPT | 文件大小:52KB | 上传时间:06-01-03
摘要:介绍了HPS研究(HeartProtectionStudy)结果。HPS: Heart Protection StudyPurposeTo determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease, bu...
文件类型:PPT | 文件大小:436KB | 上传时间:06-01-03
摘要:Combination Lipid-Altering Drug Therapy with Statins Harold Bays, MD, FACPCombination Lipid-Altering Drug Therapy with StatinsNeed for combination lipid-altering drug therapyEzetimibe and statinsBi...
文件类型:PPT | 文件大小:366KB | 上传时间:06-01-03
摘要:介绍谷固醇血症这种罕见的遗传性脂代谢紊乱Sitosterolemia: A Rare Genetic Disorder Leads to Insight into an Important Physiological Process Shailesh B。
文件类型:PPT | 文件大小:137KB | 上传时间:06-01-03
摘要:REVERSAL研究结果。Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL)Nissen SE et al。 502 with evaluable follow-upRandomization to pravastatin 40 mg/d or atrovastatin 80 mg/d for...
文件类型:PPT | 文件大小:7362KB | 上传时间:05-12-29
摘要:中国动脉粥样硬化网原创,共183张幻灯,幻灯中有3段长达10分钟的精美动画,因为文件尺寸太大(有70M),已经删除。 幻灯内容:第1部分:基础篇(58张)--(1)血脂基础(2)血脂生化学(3)脂蛋白代谢(4)脂蛋...
文件类型:PPT | 文件大小:49KB | 上传时间:05-12-29
摘要:该幻灯为CME系列幻灯之一,作者为著名的动脉粥样硬化研究专家PhilipBarter教授,主要探讨了脂蛋白(特别是ox-LDL和HDL)在动脉粥样硬化炎症中的作用,制作精美。EndotheliumVessel LumenIntimaFoam CellMonocyteC...
文件类型:PPT | 文件大小:46KB | 上传时间:05-12-29
摘要:Food and Drug AdministrationNational Cholesterol Education Program ReportsAdult Treatment Panel I (1988) Adult Treatment Panel II (1993) Adult Treatment Panel III (2001)Recommendations for Improvin...
文件类型:PPT | 文件大小:75KB | 上传时间:05-12-29
摘要:共32张,重点探讨了hs-CRP与动脉粥样硬化炎症和CHD发病的关系。 Ridker, MD, MPHBeyond Cholesterol: Predicting Cardiovascular Risk In the 21st CenturyCardiovascular RiskTotal Cholesterol Distribution: C...